e0660 Quality of life after four times intravenous infusion of bone marrow MSCs for heart failure patients

Abstract

Objective Heart failure is a complex clinical syndrome that can result from any structural or functional heart disorder, so the patients have marked limitation of physical activity and poor life quality. Some experiments have tested the safety and efficacy of intravenously injection of MSCs to restore the heart function, the goal of this study is to verify patients will have a better quality of life after stem cell transplantation. Methods The study involved 85 acute myocardial infarction patients with heart failure who had ejection fractions less than 45%. Between May 2008 and January 2010, 43 consecutive heart failure patients underwent MSCs injcetion through vein for four times in the experimental group. The number of cells prior to injection was 41.6±34.7 million cells, another 42 heart failure patients were as control group. NYHA class, 6 min walk test, Brain natridiur- eticpeptide level, transthoracic echocardiography, single-photon emission CTare obtained prior to transplatation, the patients who did not received PCI examed by MRI. Quality of life evaluated by SF36. These tests are repeated at 6 months. Results At six-month follow-up, transplantation of MSCs enhanced left-ventricular systolic function (39.12±4.54)% versus (52.08±1.02)%; emission CT (40.19±3.18)% versus (53.18±2.15)%, BNP declined (429±39) pg-ml∼ versus (152±19) pg-m-1, quality of life of the stem cell transpaltation patients were significantly improved according to the assessment of physical functioning, role limitations due to physical health, bodily pain, general health perceptions and vitality, but the social functioning, role limitations due to emotional problems and mental health were not improved. NYHA class decreased (2.08±0.25) versus (1.85±0.38), 6 min walk test increased (328.3±45.3) versus (356.8±43.2). MRI examinantion also observed the decreased infarct size in the experimental group. Conclusion Quality of life and ejection fraction were significantly improved after Bone marrow MSCs injected through four times intravenous infusion.